What type of study is this?

November 25, 2025Open Access

Real-world outcomes with palbociclib, ribociclib, and abemaciclib plus endocrine therapy in HR+/HER2− advanced breast cancer: A multicenter retrospective study

Key Points

Key points are not available for this paper at this time.

Abstract

Endocrine sensitivity/resistance and ET partner were major determinants of outcome with CDK4/6i plus ET in HR+/HER2- ABC, informing individualized treatment selection and sequencing.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Renata Duchnowska

Aleksandra Grela-Wojewoda

Karolina Winsko-Szczęsnowicz

Journals

The Breast

Actions

Institutions

Jagiellonian University

The Maria Sklodowska-Curie National Research Institute of Oncology

Gdańsk Medical University

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Real-world outcomes with palbociclib, ribociclib, and abemaciclib plus endocrine therapy in HR+/HER2− advanced breast cancer: A multicenter retrospective study

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study